“Eligible, commercially insured patients may pay as little as $0 for JEMPERLI.”
From the maker’s offer on jemperli.com, checked November 17, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Authorized generic
There isn’t one.
Not soldThere isn’t one
Regular generic
Jemperli is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.
Advanced solid tumors with dMMR (mismatch repair deficient)
What the FDA label says
JEMPERLI is a programmed death receptor‑1 (PD‑1)–blocking antibody indicated:
Endometrial Cancer
in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC).
as a single agent for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced EC, as determined by an FDA‑authorized test, that has progressed on or following prior treatment with a platinum‑containing regimen in any setting and are not candidates for curative surgery or radiation.
Microsatellite Instability–High or Mismatch Repair Deficient Locally Advanced Rectal Cancer
as a single agent for the treatment of adult patients with Stage II/III, locally advanced rectal cancer (LARC) that is microsatellite instability‑high (MSI‑H) or dMMR, as determined by an FDA‑authorized test for solid tumors.
This indication is approved under accelerated approval based on sustained clinical complete response for 12 months. The long-term risk of relapse is unknown, with additional follow-up expected. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Mismatch Repair Deficient Recurrent or Advanced Solid Tumors
as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA‑authorized test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Source: the FDA label for Jemperli (GlaxoSmithKline LLC), October 19, 2026. Full label on DailyMed
Good to know
“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.
Prices checked November 17, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/jemperli/